ArticleJournal of human genetics2026
Expanding the phenotypic spectrum of LAMA2-related disorders: Axonal neuropathy in the absence of muscular dystrophy.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The LAMA2 gene encodes the alpha-2 chain of laminin-2, a key component of the basement membrane that maintains muscle fiber stability and integrity. Mutations in this gene are linked with LAMA2-related muscular dystrophies, which includes congenital muscular dystrophy type 1 A (MDC1A) and limb-girdle muscular dystrophy autosomal recessive 23 (LGMDR23). Here, we present two siblings from one of 200 unrelated Iranian Charcot-Marie-Tooth (CMT) families, exhibiting axonal sensorimotor polyneuropathy, without any clinical signs of muscular dystrophy, carrying a homozygous variant in the LAMA2 gene. Following clinical and paraclinical assessments of the patients, genomic DNA was extracted from peripheral blood samples. Whole-exome sequencing (WES) was employed to identify potential genetic variants, and Sanger sequencing was subsequently used to confirm the detected variant. In silico prediction tools were further applied to evaluate the potential pathogenicity and functional impact of the identified variant. A homozygous missense variant in the LAMA2 gene, c.2916 T > G; p.Phe972Leu, was identified and co-segregated with the disease status within the family, whose neurological assessments confirmed axonal sensorimotor polyneuropathy. So far, only two studies have reported LAMA2 variants in patients only manifesting a neuropathy phenotype. None of these studies reported the detailed clinical data of their cases. However, our study provides further evidence of the association between LAMA2 mutations and neuropathy, and includes comprehensive clinical and paraclinical characterization of the affected individuals. Our findings underscore the importance of comprehensive genomic testing in diagnosing neuromuscular disorders and expand the phenotypic spectrum associated with LAMA2 mutations.
Indexed as
Identifiers
41765988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.